Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic drug monitoring of voriconazole in invasive aspergillosis
IRCT20151227025726N19Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Dec 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of voriconazole in Acute Invasive Aspergillosis and invasive aspergillosis (IA), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Voriconazole plasma concentration, Adverse effects and 1 more. Started Dec 2017; status: completed.
02
Drugs
voriconazole
03
Conditions
Acute Invasive Aspergillosisinvasive aspergillosis (IA)
Beyond the preview
Go deeper on IRCT20151227025726N19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20151227025726N19.